JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients

被引：0
|
作者：
Roberta Mancuso
Marina Saresella
Ambra Hernis
Ivana Marventano
Cristian Ricci
Simone Agostini
Marco Rovaris
Domenico Caputo
Mario Clerici
机构：
[1] ONLUS,Don C. Gnocchi Foundation
[2] University of Milan,Department of Physiopathology and Transplantation
来源：
Journal of Translational Medicine | / 10卷
关键词：
Cell mediated immunity; Natalizumab; MS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy
    Clausi, Valeria
    Giannecchini, Simone
    Magnani, Eliana
    Repice, Anna
    Mechi, Claudia
    Martelli, Francesco
    Azzi, Alberta
    Massacesi, Luca
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (01):
  • [42] Lack of correlation between JC Virus urinary shedding and seropositivity in Multiple Sclerosis patients treated with natalizumab
    Delbue, Serena
    Elia, Francesca
    Carloni, Camilla
    Pecchenini, Valentina
    Carluccio, Silvia
    Franciotta, Diego
    Gastaldi, Matteo
    Ferrante, Pasquale
    JOURNAL OF NEUROVIROLOGY, 2013, 19 : S23 - S24
  • [43] CONTRIBUTION OF NATALIZUMAB EXPOSURE, PRIOR IMMUNOSUPPRESSANT (IS) USE, AND JC VIRUS (JCV) INFECTION TO PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK IN NATALIZUMAB-TREATED MULTIPLE SCLEROSIS (MS) PATIENTS
    Bloomgren, G.
    Richman, S.
    Goelz, S.
    Hotermans, C.
    Hyde, R.
    Natarajan, A.
    Lee, S.
    Plavina, T.
    Subramanyam, M.
    Sandrock, A. W.
    Bozic, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 60 - 60
  • [44] Prevalence of anti-JC virus antibodies in a cohort of 1'200 natalizumab-treated MS patients
    Radji, F.
    Outteryck, O.
    Zephir, H.
    Ongagna, J. C.
    Brochet, B.
    Ouallet, J. C.
    Rumbach, L.
    Lebrun-Frenay, C.
    Debouverie, M.
    Pittion, S.
    Laplaud, D.
    Wiertlewski, S.
    Cabre, P.
    Confavreux, C.
    Vukusic, S.
    Pelletier, J.
    Audouin, B.
    Defer, G.
    Derache, N.
    Camu, W.
    Thouvenot, E.
    Tourbah, A.
    Labauge, P.
    Moreau, T.
    Fromont, A.
    Castelnovo, G.
    Clavelou, P.
    Casez, O.
    Hautecoeur, P.
    Papeix, C.
    Couturier, N.
    Viala, F.
    Liblau, R.
    Clanet, M.
    De Seze, J.
    Vermersch, P.
    Brassat, D.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S216 - S216
  • [45] CD34+hematopoietic progenitor cells are a reservoir for JC Virus in natalizumab-treated MS patients
    Monaco, Maria Chiara
    Ryschkewitsch, Caroline
    Jensen, Peter N.
    Johnson, Kory
    Major, Eugene O.
    JOURNAL OF NEUROVIROLOGY, 2012, 18 : 73 - 73
  • [46] JC Virus Reactivation during Prolonged Natalizumab Monotherapy for Multiple Sclerosis
    Chalkias, Spyridon
    Dang, Xin
    Bord, Evelyn
    Stein, Marion C.
    Kinkel, R. Philip
    Sloane, Jacob A.
    Donnelly, Maureen
    Ionete, Carolina
    Houtchens, Maria K.
    Buckle, Guy J.
    Batson, Stephanie
    Koralnik, Igor J.
    ANNALS OF NEUROLOGY, 2014, 75 (06) : 925 - 934
  • [47] Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab REPLY
    Tan, Chen S.
    Kinkel, R. Philip
    Koralnik, Igor J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25): : 2489 - 2490
  • [48] Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
    Wijburg, Martijn T.
    Kleerekooper, Iris
    Lissenberg-Witte, Birgit I.
    de Vos, Marlieke
    Warnke, Clemens
    Uitdehaag, Bernard M. J.
    Barkhof, Frederik
    Killestein, Joep
    Wattjes, Mike P.
    JAMA NEUROLOGY, 2018, 75 (07) : 827 - 833
  • [49] JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab
    Frohman, Elliot M.
    Monaco, Maria Chiara
    Remington, Gina
    Ryschkewitsch, Caroline
    Jensen, Peter N.
    Johnson, Kory
    Perkins, Molly
    Liebner, Julia
    Greenberg, Benjamin
    Monson, Nancy
    Frohman, Teresa C.
    Douek, Daniel
    Major, Eugene O.
    JAMA NEUROLOGY, 2014, 71 (05) : 596 - 602
  • [50] Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JC virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients
    Bloomgren, G.
    Richman, S.
    Hotermans, C.
    Subramanyam, M.
    Goelz, S.
    Natarajan, A.
    Lee, S.
    Plavina, T.
    Scanlon, J.
    Sandrock, A.
    Bozic, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S452
12345